| scholarly article | Q13442814 |
| P50 | author | Alessandra Moretti | Q42649318 |
| Tessa Werner | Q59611325 | ||
| Kaja Breckwoldt | Q88424435 | ||
| P2093 | author name string | Norbert Huebner | |
| Herbert Schulz | |||
| Arne Hansen | |||
| Thomas Eschenhagen | |||
| Christiane Neuber | |||
| Thomas Schulze | |||
| Alexandra Eder | |||
| Ingra Mannhardt | |||
| Marc N Hirt | |||
| Sebastian Schaaf | |||
| Torsten Christ | |||
| Birgit Klampe | |||
| Anika Benzin | |||
| David Letuffe-Brenière | |||
| P2860 | cites work | Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology | Q21134989 |
| Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture | Q24630666 | ||
| Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes | Q27324739 | ||
| Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator | Q27343160 | ||
| Inotropes. | Q27692096 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes | Q28081697 | ||
| Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature | Q28379324 | ||
| The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart | Q28585488 | ||
| Increased afterload induces pathological cardiac hypertrophy: a new in vitro model | Q30528600 | ||
| Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays | Q30558954 | ||
| Design and formulation of functional pluripotent stem cell-derived cardiac microtissues | Q30559093 | ||
| Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes | Q30574106 | ||
| Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell–Derived Cardiomyocytes to Functional Preclinical Safety Assays | Q30629611 | ||
| Impact of detubulation on force and kinetics of cardiac muscle contraction. | Q33672949 | ||
| A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. | Q33722486 | ||
| Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue | Q34161831 | ||
| High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. | Q34213428 | ||
| Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming | Q34245487 | ||
| Binding specificity of sea anemone toxins to Nav 1.1-1.6 sodium channels: unexpected contributions from differences in the IV/S3-S4 outer loop. | Q34323654 | ||
| Cardiac arrhythmia induced by genetic silencing of 'funny' (f) channels is rescued by GIRK4 inactivation | Q34392423 | ||
| A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes | Q34439974 | ||
| Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 | ||
| Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart | Q36003980 | ||
| Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers | Q36176876 | ||
| Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias | Q36254286 | ||
| Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. | Q36348901 | ||
| Regionally diverse mitochondrial calcium signaling regulates spontaneous pacing in developing cardiomyocytes. | Q36497604 | ||
| MICE models: superior to the HERG model in predicting Torsade de Pointes | Q36968169 | ||
| Pluripotent stem cell models of human heart disease | Q37256433 | ||
| Force frequency relationship of the human ventricle increases during early postnatal development | Q37458344 | ||
| Distribution and function of sodium channel subtypes in human atrial myocardium | Q37532412 | ||
| Physiological aspects of cardiac tissue engineering | Q38009793 | ||
| Calcium-agonists | Q38178449 | ||
| Cardiac tissue engineering: state of the art. | Q38179331 | ||
| A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm. | Q38546437 | ||
| L-type Ca2+ channel responses to bay k 8644 in stem cell-derived cardiomyocytes are unusually dependent on holding potential and charge carrier | Q38963696 | ||
| Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro | Q39252624 | ||
| Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes | Q39759039 | ||
| Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes | Q41192534 | ||
| Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells | Q41272675 | ||
| Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes | Q41652755 | ||
| Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells | Q41994668 | ||
| Intracellular calcium dynamics and acceleration of sinus rhythm by beta-adrenergic stimulation | Q42540447 | ||
| Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model | Q42709339 | ||
| Development of a drug screening platform based on engineered heart tissue | Q43071445 | ||
| Effects of postnatal maturation on postrest potentiation in isolated rabbit atria | Q44610495 | ||
| An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility | Q46145054 | ||
| Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform | Q46247292 | ||
| Ca2+ Channel Activators Reveal Differential L-Type Ca2+ Channel Pharmacology between Native and Stem Cell-Derived Cardiomyocytes | Q46342052 | ||
| In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes | Q46569292 | ||
| Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. | Q46675989 | ||
| Mechanism of action of a novel human ether-a-go-go-related gene channel activator | Q46801187 | ||
| Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle | Q51168469 | ||
| A TTX-sensitive inward sodium current contributes to spontaneous activity in newborn rabbit sino-atrial node cells | Q51574206 | ||
| Generation of strip-format fibrin-based engineered heart tissue (EHT). | Q53488792 | ||
| High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays | Q53555497 | ||
| Ryanodine alteration of the contractile state of rat ventricular myocardium. Comparison with dog, cat, and rabbit ventricular tissues | Q71140650 | ||
| Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure | Q73257762 | ||
| Single cell mechanics of rat cardiomyocytes under isometric, unloaded, and physiologically loaded conditions | Q79735185 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 29-42 | |
| P577 | publication date | 2016-05-19 | |
| P1433 | published in | Stem Cell Reports | Q27725039 |
| P1476 | title | Human Engineered Heart Tissue: Analysis of Contractile Force | |
| P478 | volume | 7 |
| Q91786622 | 3D Cardiac Cell Culture: A Critical Review of Current Technologies and Applications |
| Q48232901 | 3D aggregate culture improves metabolic maturation of human pluripotent stem cell derived cardiomyocytes |
| Q64892613 | 3D printed micro-scale force gauge arrays to improve human cardiac tissue maturation and enable high throughput drug testing. |
| Q90254871 | A tissue-engineered scale model of the heart ventricle |
| Q52606323 | Advanced maturation of human cardiac tissue grown from pluripotent stem cells. |
| Q47144807 | Ajmaline blocks INa and IKr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters. |
| Q91893638 | An in vitro model of myocardial infarction |
| Q92984895 | Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium |
| Q46375849 | Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening |
| Q47270959 | Bioengineered Cardiac Tissue Based on Human Stem Cells for Clinical Application |
| Q64091759 | Bioengineering adult human heart tissue: How close are we? |
| Q95319975 | Biomimetic Model of Contractile Cardiac Tissue with Endothelial Networks Stabilized by Adipose-Derived Stromal/Stem Cells |
| Q92557859 | Biowire Model of Interstitial and Focal Cardiac Fibrosis |
| Q50692262 | Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae. |
| Q88613563 | CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy |
| Q89433765 | Can We Engineer a Human Cardiac Patch for Therapy? |
| Q51110763 | Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. |
| Q89519147 | Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine |
| Q47160787 | Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. |
| Q92853671 | Case Report on: Very Early Afterdepolarizations in HiPSC-Cardiomyocytes-An Artifact by Big Conductance Calcium Activated Potassium Current (Ibk,Ca) |
| Q90621737 | Chronic intermittent tachypacing by an optogenetic approach induces arrhythmia vulnerability in human engineered heart tissue |
| Q64105859 | Chronic optical pacing conditioning of h-iPSC engineered cardiac tissues |
| Q55293161 | Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks. |
| Q50087955 | Co-Differentiation of Human Pluripotent Stem Cells-Derived Cardiomyocytes and Endothelial Cells from Cardiac Mesoderm Provides a Three-Dimensional Model of Cardiac Microtissue |
| Q92628552 | Concise Review: Reduction of Adverse Cardiac Scarring Facilitates Pluripotent Stem Cell-Based Therapy for Myocardial Infarction |
| Q92856760 | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
| Q90289902 | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Usi |
| Q50420944 | Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. |
| Q46307292 | Contractile force generation by 3D hiPSC-derived cardiac tissues is enhanced by rapid establishment of cellular interconnection in matrix with muscle-mimicking stiffness |
| Q50100689 | Current State-of-the-Art 3D Tissue Models and Their Compatibility with Live Cell Imaging. |
| Q64950235 | DNA methylation profiling allows for characterization of atrial and ventricular cardiac tissues and hiPSC-CMs. |
| Q48061816 | Differentiation of cardiomyocytes and generation of human engineered heart tissue |
| Q96126759 | Drug response analysis for scaffold-free cardiac constructs fabricated using bio-3D printer |
| Q99548968 | Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study |
| Q38750884 | Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs) |
| Q40156224 | Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes |
| Q64059367 | Femtosecond laser-based nanosurgery reveals the endogenous regeneration of single Z-discs including physiological consequences for cardiomyocytes |
| Q92756466 | Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency |
| Q38675863 | From iPSC towards cardiac tissue-a road under construction |
| Q93216769 | Functional arrays of human pluripotent stem cell-derived cardiac microtissues |
| Q92480289 | Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes |
| Q54949440 | Generation of functional cardiomyocytes from rat embryonic and induced pluripotent stem cells using feeder-free expansion and differentiation in suspension culture |
| Q57072496 | Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery |
| Q58705541 | Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor |
| Q91363886 | Human Cardiac Ventricular-Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Two-Tiered Assay for Inotropic Responses |
| Q47377047 | Human Pluripotent Stem Cell-Derived Cardiac Tissue-like Constructs for Repairing the Infarcted Myocardium |
| Q39345477 | Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. |
| Q91723707 | Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model |
| Q33906188 | Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. |
| Q30843677 | Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue |
| Q28079217 | Inherited heart disease - what can we expect from the second decade of human iPS cell research? |
| Q47819879 | Inspiration from heart development: Biomimetic development of functional human cardiac organoids |
| Q97094349 | Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment |
| Q58577756 | Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits |
| Q96343427 | Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics |
| Q41718114 | Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires |
| Q89591498 | Leave the Light On: Chronic Optogenetic Tachypacing of Human Engineered Cardiac Tissue Constructs |
| Q64074244 | Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells |
| Q50074646 | Low Resting Membrane Potential and Low Inward Rectifier Potassium Currents Are Not Inherent Features of hiPSC-Derived Cardiomyocytes |
| Q47241525 | MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo. |
| Q91557750 | Molecular mechanisms of arrhythmogenic cardiomyopathy |
| Q51418460 | Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development |
| Q92217698 | Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics |
| Q89916588 | Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease |
| Q49884846 | Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report |
| Q38720689 | Quantification of Cardiomyocyte Alignment from Three-Dimensional (3D) Confocal Microscopy of Engineered Tissue |
| Q41573786 | Real-Time Force and Frequency Analysis of Engineered Human Heart Tissue Derived from Induced Pluripotent Stem Cells Using Magnetic Sensing. |
| Q93348265 | Recent Advances in Body-on-a-Chip Systems |
| Q89857680 | Regulation of ICa,L and force by PDEs in human-induced pluripotent stem cell-derived cardiomyocytes |
| Q91945248 | Remote Magnetic Nanoparticle Manipulation Enables the Dynamic Patterning of Cardiac Tissues |
| Q51340305 | Safety pharmacology methods and models in an evolving regulatory environment |
| Q90197028 | Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes |
| Q42408860 | Small molecule absorption by PDMS in the context of drug response bioassays. |
| Q50219235 | Structural Immaturity of Human iPSC-Derived Cardiomyocytes: In Silico Investigation of Effects on Function and Disease Modeling |
| Q37711224 | Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells |
| Q64080614 | Three-dimensional microengineered models of human cardiac diseases |
| Q96304765 | Toward Cardiac Regeneration: Combination of Pluripotent Stem Cell-Based Therapies and Bioengineering Strategies |
| Q64285907 | User-Friendly and Parallelized Generation of Human Induced Pluripotent Stem Cell-Derived Microtissues in a Centrifugal Heart-on-a-Chip |
Search more.